Your session is about to expire
← Back to Search
PRMT5 Inhibitor
PRT811 for Brain Tumor
Phase 1
Waitlist Available
Research Sponsored by Prelude Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through approximately 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing PRT811, a new drug, in patients with advanced cancers who have no other treatment options. PRT811 works by blocking a protein that helps cancer cells grow.
Eligible Conditions
- Solid Tumors
- Brain Tumor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through approximately 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through approximately 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To describe dose limiting toxicities (DLT) of PRT811
To determine the maximally tolerated dose (MTD)
To determine the recommended phase 2 dose (RP2D) and schedule of PRT811
Secondary study objectives
To describe any anti-tumor activity of PRT811
To describe the adverse event profile and tolerability of PRT811
To describe the pharmacokinetic profile of PRT811
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: PRT811Experimental Treatment1 Intervention
PRT811 will be administered orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRT811
2019
Completed Phase 1
~90
Find a Location
Who is running the clinical trial?
Prelude TherapeuticsLead Sponsor
10 Previous Clinical Trials
971 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger